GPRC5D Antibody Variants for Precise CDR Residue Affinity Tuning
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody discovery methods face challenges in accurately identifying residues within complementarity-determining regions (CDRs) of antibodies that affect binding affinity, particularly for G-protein-coupled receptor family C group 5 member D (GPRC5D), due to structural complexities and limited understanding of downstream signaling pathways, complicating the development of effective therapeutic antibodies for multiple myeloma.
Innovation Solution
Development of novel antibodies and variants thereof with specific amino acid sequences in the heavy and light chain variable regions (HVR and LVR) that enhance binding to GPRC5D, achieving at least a 20-80% increase in binding reactivity compared to wild-type antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current antibody discovery methods are used to identify residues in CDRs, then the process can be completed with existing tools, but the accuracy of identifying residues that affect binding affinity is insufficient
Solution Approach 1:
The patent segments the CDR regions into individual residue positions and systematically evaluates each residue's contribution to binding affinity through structured mutagenesis. By dividing the complex binding interface into discrete, testable units (individual amino acid positions), the method achieves more precise identification of critical residues while maintaining experimental reliability.
Solution Approach 2:
The patent systematically varies amino acid parameters at each CDR position, testing multiple substitutions to understand how specific residue changes affect binding. This parameter-based approach allows for accurate identification of residues that significantly impact binding affinity by comparing the effects of different amino acid substitutions at each position.
2Manufacturing precision
If comprehensive antibody variants are generated to improve binding affinity, then better therapeutic candidates can be identified, but the complexity of the discovery process increases
Solution Approach 1:
The patent applies segmentation by focusing mutagenesis efforts on specific CDR regions rather than generating random comprehensive variants. This targeted approach reduces the complexity of the discovery process while still identifying high-affinity variants by concentrating variations where they are most likely to impact binding.
Solution Approach 2:
The patent applies local quality by introducing variations specifically in the CDR regions where binding interactions occur, rather than uniformly across the entire antibody sequence. This localized approach to variant generation improves binding affinity identification while maintaining manageable process complexity.
3Loss of information
If structural complexities of GPRC5D are addressed through detailed characterization, then better understanding of binding mechanisms is achieved, but the time and resources required increase
Solution Approach 1:
The patent applies preliminary action by first identifying and characterizing the CDR regions before conducting comprehensive binding studies. This preliminary characterization of the binding interface provides a foundation for understanding binding mechanisms more efficiently, as the critical regions are already mapped before detailed mechanistic studies begin.
Solution Approach 2:
The patent incorporates feedback loops where binding data from initial experiments informs subsequent mutagenesis and characterization efforts. This iterative feedback process efficiently uncovers binding mechanisms by using experimental results to guide the next round of investigations, reducing overall characterization time.
Data Source
AI summary
The present disclosure describes compositions and methods related to GPRC5D binding agents.